PROTAC BTK Degraders for Potent Targeted Protein Knockdown
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for more potent BTK inhibitors or degraders that can effectively target BTK via alternative strategies, such as through degradation, to treat autoimmune and inflammatory diseases and cancers.
Innovation Solution
Development of PROTAC compounds that act as BTK degraders or inhibitors, comprising specific heterobifunctional molecules capable of binding to BTK and E3 ligase, leading to the ubiquitination and subsequent degradation of the BTK protein.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional BTK inhibitors are used, then BTK activity is inhibited, but the inhibitory effect is not potent enough and alternative strategies are needed
Solution Approach 1:
Instead of using traditional inhibitors that block BTK activity, the patent employs PROTAC molecules that induce BTK degradation through the proteasome pathway. This inverted approach transforms the mechanism from activity inhibition to protein degradation, achieving more potent and sustained therapeutic effects against BTK-driven diseases.
Solution Approach 2:
The patent introduces E3 ligase as an intermediary component in the BTK degradation process. The PROTAC molecule acts as a bridge that recruits E3 ligase to ubiquitinate BTK, which then targets BTK for proteasomal degradation. This intermediary mechanism enables selective and efficient BTK degradation while maintaining specificity.
2Reliability
If BTK is degraded through PROTAC mechanism, then BTK protein levels are reduced, but the molecular complexity of the degrader increases
Solution Approach 1:
The PROTAC molecule is segmented into distinct functional domains: a BTK-binding ligand portion, a linker region, and an E3 ligase-recruiting portion. This segmentation allows each component to perform its specific function independently while working together as an integrated system to achieve BTK degradation.
Solution Approach 2:
The patent constructs PROTAC molecules as composite structures combining different chemical moieties with specific functions. The BTK ligand portion binds to BTK, the linker provides spatial separation and flexibility, and the E3 ligase ligand recruits degradation machinery. This composite design enables sophisticated functionality while maintaining molecular precision.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PROTAC compounds effectively inhibit and degrade BTK, offering a therapeutic approach for treating diseases mediated by BTK, including cancers, by reducing BTK activity and promoting its degradation.
Implementation Method 1
bifunctional compounds composed of a target protein-binding moiety and an E3 ubiquitin ligase-binding moiety have been shown to induce proteasome-mediated degradation of selected proteins
Data Source
AI summary
The present disclosure relates to compounds that function as degraders or inhibitors of BTK. The present disclosure further relates to pharmaceutical compositions comprising them, and to their use in the treatment of diseases mediated by BTK, such as cancer.